FAB 114Alternative Names: FAB114
Latest Information Update: 21 Jan 2016
At a glance
- Originator Ferrer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 21 Jan 2016 Preclinical trials in Non-Hodgkin's lymphoma in Spain (unspecified route)
- 21 Jan 2016 Preclinical trials in Chronic lymphocytic leukaemia in Spain (unspecified route)